三级小说欧洲区亚洲区_国产不卡一区_免费不卡中文字幕在线_91亚洲一区_久久精品超碰_日韩伦理一区_激情不卡一区二区三区视频在线_国产精品www._久久精品三级_日韩在线a电影_se01亚洲视频_五月天激情综合网

China's artificial intelligence-driven drug discovery is accelerating its role as a prominent player in global biotech. Experts and industry insiders said the sector is drawing unprecedented international attention, even though no AI-discovered drug has yet reached the market.

According to SDIC Securities, the global AI-driven drug market has more than doubled since 2021, hitting $1.76 billion in 2024, with a compound annual growth rate of more than 30 percent.

In China, the pace is even faster from 70 million yuan ($9.74 million) in 2019 to 410 million yuan in 2023, with a CAGR of 57.4 percent. Lead-Leo Research Institute projects nearly 70 percent annual growth from 2024 to 2028, when the market could top 5.86 billion yuan.

China's AI drug sector has also been striking deals with Big Pharma. This year alone, Syneron Bio inked a $3.4 billion agreement with AstraZeneca, while Helixon signed a $1.72 billion partnership with Sanofi, among others.

"These collaborations show Chinese AI drug-discovery capabilities are gaining global recognition," said Fang Yang, executive director for healthcare and biotech at CEC Capital. "The industry is entering a new phase of going global and proving it can deliver results."

The most recent deal capturing attention is China's XtalPi Holdings Ltd's $6 billion partnership with US biotech firm DoveTree. It ranks among the largest license-out deals in China's biopharma history.

Under the deal, announced on Aug 5, XtalPi will deploy its AI platforms to run preclinical research on a mix of large — and small-molecule programs, including several targets picked by DoveTree. The US partner will hold exclusive worldwide rights to develop and commercialize the resulting drug candidates.

XtalPi has already pocketed $51 million upfront, far exceeding its total 2024 revenue of 266 million yuan and is in line for another $49 million in near-term payments and as much as $5.89 billion in milestones and royalties.

"AI can optimize molecular structures and streamline the earliest stages of drug research and development," said Chu Lei, a researcher at the Healthcare Executive Institute. "XtalPi's role is to deliver ready-to-test clinical candidates straight to DoveTree's labs."

Still, the potential of AI in biotech is promising. Traditional drug development can take more than a decade and cost more than $1 billion. AI, particularly deep-learning models, can speed up target screening, molecular design, and even trial planning. Consultancy McKinsey experts estimated that AI could shrink the time from lab to patient to a tenth of current timelines.

Ren Feng, co-CEO of Insilico Medicine, described the global AI-driven biotech sector as moving into its 2.0 phase. The first wave dating back three decades relied on physics-based computer-aided design. The arrival of generative AI around 2013 marked a turning point, allowing algorithms to create novel molecules from scratch by drawing on vast troves of historical data.

The next stage, Ren said, will see AI embedded in every step of drug R&D, from target discovery to clinical management — ushering in what he calls the "3.0 era" of fully integrated, intelligent drug development.

Policy tailwinds are reinforcing the trend. In November 2024, the National Health Commission and two other ministries issued a blueprint for AI in healthcare, naming intelligent drug discovery and development and AI-assisted clinical trials as priority areas.

Local governments are following suit. On Aug 12, Zhejiang province laid out a plan to build a national AI medical application base by 2027, aimed at fostering homegrown innovators, attracting composite talent, and building a complete AI healthcare industry chain.

Despite the surge in dealmaking and investment, industry experts stress most AI-driven agreements today, including XtalPi's, focus on preclinical work. "No AI-discovered drug has yet been approved anywhere in the world, meaning the commercial loop remains incomplete," Chu noted.

The World Internet Conference (WIC) was established as an international organization on July 12, 2022, headquartered in Beijing, China. It was jointly initiated by Global System for Mobile Communication Association (GSMA), National Computer Network Emergency Response Technical Team/Coordination Center of China (CNCERT), China Internet Network Information Center (CNNIC), Alibaba Group, Tencent, and Zhijiang Lab.

三级小说欧洲区亚洲区_国产不卡一区_免费不卡中文字幕在线_91亚洲一区_久久精品超碰_日韩伦理一区_激情不卡一区二区三区视频在线_国产精品www._久久精品三级_日韩在线a电影_se01亚洲视频_五月天激情综合网
国产精成人品2018| 99pao成人国产永久免费视频 | 精品国产精品国产偷麻豆| 欧美va天堂| 国产精品99久久精品| 日韩精品成人在线观看| 激情综合在线| 亚洲第一区色| 成人羞羞视频播放网站| 国产一区二区三区91| 97se亚洲| 91成人福利| 日韩av网站在线观看| 中文视频一区| 日韩午夜av在线| 欧美日韩国产免费观看视频| 伊伊综合在线| 精品捆绑调教一区二区三区| 中文在线а√在线8| 精品国产免费人成网站| 国产一二在线播放| 国产不卡人人| 久久免费高清| 亚洲精品网址| 香蕉精品久久| 免费精品视频| 日本aⅴ亚洲精品中文乱码| 久久国产高清| 亚洲久草在线| 日韩中文字幕亚洲一区二区va在线| 免费视频亚洲| 综合国产视频| 国产日韩视频| 福利在线免费视频| 91精品国产乱码久久久久久久 | 国产欧美亚洲一区| 国产一卡不卡| 国产a亚洲精品| 亚洲高清激情| 亚洲日本免费电影| 青青草国产精品亚洲专区无| 国产日韩欧美一区| www.九色在线| 欧美+亚洲+精品+三区| 在线观看亚洲精品福利片| 日本99精品| 国产乱码午夜在线视频| 四虎884aa成人精品最新| 一本色道久久精品| 日本午夜精品视频在线观看| 国产精品久久久免费| 国产一区二区三区91| 亚洲不卡av不卡一区二区| 久久亚洲电影| 97精品一区| 一区免费在线| 日韩av网站免费在线| 日韩精品电影| 青青青国产精品| 日韩在线精品| 91精品国产一区二区在线观看| 在线手机中文字幕| 在线精品观看| 国产精品7m凸凹视频分类| 欧美日韩a区| 午夜精品亚洲| 伊伊综合在线| 国产私拍福利精品视频二区| 欧美日中文字幕| 精品一区二区三区在线观看视频| 美女毛片一区二区三区四区| 国产精品一在线观看| 久久不射中文字幕| 亚洲一级少妇| 久久中文欧美| 综合欧美亚洲| 99香蕉国产精品偷在线观看 | 黄色av日韩| 日韩一区二区在线免费| 亚洲一区二区三区免费在线观看| 精品伊人久久| 国产精品va| 国产伦一区二区三区| 亚洲开心激情| 国产精品毛片| 亚洲第一区色| 日韩精品2区| 中文字幕在线视频网站| 卡一精品卡二卡三网站乱码| 91精品麻豆| 青青草伊人久久| 日本三级亚洲精品| 91精品国产自产精品男人的天堂| 夜久久久久久| 视频在线在亚洲| 国内精品99| 欧美高清不卡| 中文日韩欧美| 99在线观看免费视频精品观看| 久久青草久久| 日韩深夜视频| 欧美一区二区三区免费看| 日韩中文字幕不卡| 亚洲深深色噜噜狠狠爱网站| 国产韩日影视精品| 激情久久久久久| 国产亚洲精品v| 在线精品亚洲| 国产精品mv在线观看| 麻豆视频一区二区| 日韩精品永久网址| 欧美性感美女一区二区 | 欧美片第1页| 丁香六月综合| 午夜精品亚洲| 日本综合视频| 精品女同一区二区三区在线观看| 成午夜精品一区二区三区软件| 国产一区二区三区91| a国产在线视频| 久久中文亚洲字幕| 日本大胆欧美人术艺术动态| 日本国产亚洲| 美女一区网站| 亚洲91在线| 中文字幕在线看片| 亚洲精品在线观看91| 综合激情视频| 视频在线不卡免费观看| 久久久男人天堂| 在线免费观看亚洲| 精品视频在线观看网站| 成人日韩精品| 蜜桃视频一区二区| 国产成人黄色| 综合激情一区| 久久国产成人午夜av影院宅| 喷白浆一区二区| av免费不卡国产观看| 久久亚洲风情| 国产一区二区三区久久 | 伊人久久国产| 在线精品亚洲| 99精品视频精品精品视频| 日韩一区精品视频| 97人人精品| 日韩精品视频网站| 亚洲www啪成人一区二区| 日韩高清欧美激情| 国产亚洲一区二区手机在线观看 | 精品精品国产三级a∨在线| 精品在线91| 久久这里只有| 亚洲精品婷婷| 亚洲欧洲午夜| 国产精品亚洲一区二区三区在线观看| 午夜日韩影院| 激情综合网址| 91精品蜜臀一区二区三区在线| 国产精品免费99久久久| 国产精品日本| 午夜精品成人av| 精品久久一区| 欧美日韩 国产精品| 日韩视频一区二区三区在线播放免费观看| 免费日韩成人| 欧美午夜网站| 日本少妇精品亚洲第一区| 婷婷综合亚洲| 99热精品久久| 欧美日韩国产传媒| 不卡在线一区| 久久久久久美女精品| 国产精品精品| 久久精品午夜| 国产成人在线中文字幕| 免费在线亚洲欧美| 久久国内精品视频| 久久国产三级| 国产乱论精品| 国产欧美三级| 国产精品嫩模av在线| 国产精品久久久免费| 国产精品视频首页| 精品一区av| 欧美日一区二区在线观看| 日本v片在线高清不卡在线观看| 亚洲一区激情| 人人爽香蕉精品| 亚洲三级在线| 国产精品一区免费在线| 国产精品毛片aⅴ一区二区三区| 国产欧美啪啪| 久久精品天堂| 欧美手机在线| 久久亚洲影院| 日韩免费精品| 精品成人18| 成人免费网站www网站高清| 日韩国产一区二区|